Targeted placement of the left ventricular lead did not improve outcomes in patients with heart failure undergoing cardiac resynchronization therapy, according to results presented in a Hot Line session at ESC Congress 2026 and published simultaneously in The Lancet.
Targeted Lead Placement in Cardiac Resynchronization Therapy Shows No Improvement in Patient Outcomes
A study presented at ESC Congress 2026 found that targeted placement of the left ventricular lead in cardiac resynchronization therapy did not yield better outcomes for heart failure patients compared to standard placement. This research, published in The Lancet, is relevant for medical professionals in Iran as it may influence treatment protocols for heart failure patients.
👥 Key Players
📰 What Happened
A study presented at ESC Congress 2026 found that targeted placement of the left ventricular lead in cardiac resynchronization therapy did not yield better outcomes for heart failure patients compared to standard placement. This research was published in The Lancet, highlighting its significance in the medical community.
- Targeted lead placement did not improve patient outcomes.
- The findings may influence treatment protocols for heart failure patients.
💡 Why It Matters
📚 Background
Cardiac resynchronization therapy is a treatment for heart failure that aims to improve the heart's efficiency by coordinating its contractions. Understanding the effectiveness of lead placement is crucial for optimizing patient outcomes.
🏷️ Entities Mentioned
Translated from the original and edited for English readers. View original source →
Translation confidence: 100%